Fig. 1: IL-37D transgene attenuates obesity, insulin resistance, and hepatic steatosis in HFD-fed mice. | Cell Death Discovery

Fig. 1: IL-37D transgene attenuates obesity, insulin resistance, and hepatic steatosis in HFD-fed mice.

From: IL-37 isoform D acts as an inhibitor of soluble ST2 to boost type 2 immune homeostasis in white adipose tissue

Fig. 1

IL-37Dtg and WT mice were administrated with HFD or NCD for 18 or 23 weeks (n = 4–8 per group). Body weight recorded during (a) and after (b) 18 weeks of diet intervention. Glucose tolerance test (GTT, c) and insulin tolerance test (ITT, e) were performed in mice after 11 or 13 weeks of HFD, respectively, the values of area under the curve in GTT (d) and ITT (f) were measured. After 18 or 23 weeks of HFD, serum insulin (g) was detected; the morphology (h), weight (i), and triglyceride (TG) contents (j) of liver tissues are shown; the hematoxylin & eosin (H&E) and Oil Red O staining were performed in liver sections (k). Data represent mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, determined by two-way ANOVA (a–g, i–j).

Back to article page